Neutrophilic inflammation and epithelial barrier disruption in nasal polyps characterize non-steroidal anti-inflammatory drug exacerbated respiratory disease
- PMID: 34921681
- PMCID: PMC8960346
- DOI: 10.1111/all.15198
Neutrophilic inflammation and epithelial barrier disruption in nasal polyps characterize non-steroidal anti-inflammatory drug exacerbated respiratory disease
Conflict of interest statement
Conflict of interest:
For Elina Jerschow:
Advisory Board - GlaxoSmithKline, Sanofi-Regeneron, Novartis/Genentech.
Consultant –GlaxoSmithKline. None of these are relevant to this work.
Other authors declare no conflict of interest
Figures

References
-
- Khan A, Vandeplas G, Huynh TMT, Joish VN, Mannent L, Tomassen P, et al. The Global Allergy and Asthma European Network (GALEN rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps. Rhinology. 2019;57(1):32–42. - PubMed
-
- Kowalski ML, Agache I, Bavbek S, Bakirtas A, Blanca M, Bochenek G, et al. Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD)-a EAACI position paper. Allergy. 2019;74(1):28–39. - PubMed
-
- Cornet M, Kristina K, Bas R, Koos Z, Wytske F. Expression profiling of nasal polyp epithelial cells identifies two distinct phenotypes and suggests a role for neurogenic inflammation. Clin Trans Allergy. 2015. Dec;5(4):1-.
-
- Callejas-Díaz B, Fernandez G, Fuentes M, Martínez-Antón A, Alobid I, Roca-Ferrer J et al.. Integrated mRNA and microRNA transcriptome profiling during differentiation of human nasal polyp epithelium reveals an altered ciliogenesis. Allergy 2020;75:2548–2561. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical